Motivational Interviewing at Intake (MII) for Treatment Adherence

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Turning Point Recovery Center, Albuquerque, NM
Treatment Adherence+1 More
Motivational Interviewing at Intake (MII) - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This K23 study is an effectiveness-implementation hybrid type I design to determine the effectiveness of Motivational Interviewing at Intake (MII), relative to intake-as-usual on client engagement and mechanisms of engagement among adults seeking outpatient addiction treatment. We also will obtain personnel feedback on the feasibility of implementing MII into standard practice by having personnel from the addiction treatment study sites complete implementation climate measures before Motivational Interviewing (MI) training and post-clinical trial, as well as an individual interview on implementation feasibility post-trial.

Eligible Conditions

  • Treatment Adherence
  • Drug Abuse

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 2 Secondary · Reporting Duration: baseline and 1 year

1 hour post-intake
Score on therapeutic alliance on the Working Alliance Inventory (WAI) at 1-hour post-intake
Hour 1
Change from baseline in client readiness to enter treatment on the University of Rhode Island Change Assessment Scale (URICA) at 1 hour post-intake
baseline and 1 year
Change from baseline in organizational capability to change on the Change Process Capability Questionnaire (CPCQ) at Year 1
Change from baseline in organizational readiness to change on the Readiness for Organizational Change (ROC) at 1 year
Change from baseline in organizational readiness to change on the Texas Christian University-Organizational Readiness to Change (TCU-ORC) at 1 year
up to 36 weeks
Number of participants who attended the first outpatient treatment program session based on electronic medical record review
Number of participants who completed the three-month outpatient treatment program based on electronic medical record review
Number of treatment sessions attended during the three-month outpatient treatment program based on electronic medical record review

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Intake as Usual (IAU)
1 of 2
Motivational Interviewing at Intake (MII)
1 of 2
Active Control
Experimental Treatment

150 Total Participants · 2 Treatment Groups

Primary Treatment: Motivational Interviewing at Intake (MII) · No Placebo Group · N/A

Motivational Interviewing at Intake (MII)
Behavioral
Experimental Group · 1 Intervention: Motivational Interviewing at Intake (MII) · Intervention Types: Behavioral
Intake as Usual (IAU)
Behavioral
ActiveComparator Group · 1 Intervention: Intake as Usual (IAU) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline and 1 year
Closest Location: Turning Point Recovery Center · Albuquerque, NM
Photo of new mexico 1Photo of new mexico 2Photo of new mexico 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Treatment Adherence
0 CompletedClinical Trials

Who is running the clinical trial?

University of New MexicoLead Sponsor
333 Previous Clinical Trials
3,536,043 Total Patients Enrolled
1 Trials studying Treatment Adherence
48 Patients Enrolled for Treatment Adherence
National Institute on Drug Abuse (NIDA)NIH
2,203 Previous Clinical Trials
5,610,329 Total Patients Enrolled
1 Trials studying Treatment Adherence
80 Patients Enrolled for Treatment Adherence
Margo Hurlocker, PhDPrincipal InvestigatorUniversity of New Mexico

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are currently employed at one of the two outpatient addiction treatment programs.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.